Evidence map›Paper›PMID 42137265›Full record

ArticleMolecular therapy. Advances2026

Spatial mapping of barcoded, brain-tropic AAVs using multiplexed RNA

Youssef Fouani, Martin Oti, Sebastian Jarosch, Dragica Blazevic, Matthias Johannes Duechs, Stephanie Ketterer, Robert Becker, Sarah Abele, Benjamin Strobel, Tanja Schoenberger and 7 more

Abstract read
In one paragraph

Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Youssef FouaniEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Martin OtiComputational Innovation, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Sebastian JaroschDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Dragica BlazevicEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Matthias Johannes DuechsEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Stephanie KettererEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Robert BeckerEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Sarah AbeleDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Benjamin StrobelDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Tanja SchoenbergerDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Gregorio Alanis-LobatoComputational Innovation, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach, Germany.
Werner RustDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Christian SchoenEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Matthias KlugmannEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Udo MaierEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Jonas DoerrDrug Discovery Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.
Stefan MichelfelderEye Health & Research Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gene therapy cargo delivery to specific cell types in the central nervous system (CNS) remains a major challenge for the development of adeno-associated virus (AAV) vectors as a therapeutic modality. Here, we leverage high-plex

Indexed as

AAV capsid engineeringadeno-associated virusBraingene therapyspatial transcriptomicstropic AAV vectors

Identifiers

PMID42137265
PMCPMC13148934

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.